Supplementary Information1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
Open Access
- 4 February 2026
- other
- Published by American Association for Cancer Research (AACR)